Connect Sign In
February is American Heart Month, and ARUP Consult has current resources on testing for acute coronary syndrome, heart failure, and atherosclerotic cardiovascular disease markers.
MetaCensus is the first open-access data repository built for peer-review and meta-analysis. The tool aims to break down stakeholder silos to quickly achieve scientific consensus.
Researchers at ARUP Laboratories published more than 130 peer-reviewed articles and contributed more than 135 posters or presentations at medical conferences in FY2023 to advance laboratory medicine.
ARUP and the University of Utah Department of Pathology have announced that ARUP’s executive vice president, Julio Delgado, MD, MS, will be the inaugural holder of a new presidential endowed chair.
Four different algorithms to lead clinicians through the correct approach to thyroid testing are available on arupconsult.com.
Lab testing is key to thyroid disease diagnosis and proper treatment but can be challenging. ARUP Consult’s thyroid disease testing resources are divided into easy-to-navigate topics and algorithms.
More than 250 ARUP employees participated in Advanced Instruments’ Pipetting Challenge this year. Seven ARUP teams finished in the top 10 in the nationwide competition.
PhD scientists, analysts, and medical directors within ARUP’s Hematopathology department meet often to ensure clinicians and patients receive a diagnosis that reflects an integrated approach.
Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results.
Days before the public comment period ends, ARUP Laboratories’ experts host webinar to educate and encourage attendees to provide comments on the FDA’s proposed rule to regulate lab-developed tests.
ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.
ARUP experts seek to increase understanding of the FDA’s proposed rule to regulate lab-developed tests as medical devices and the impact on hospitals and patients during a webinar on November 29.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
